Recent Updates
Recently added Catalysts
ACRS Positive Sentiment

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Tuesday, March 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Aclaris Therapeutics will participate in the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026. CEO Dr. Neal Walker and the senior leadership team will engage in a fireside chat. The event will be webcast live and archived on Aclaris' website for at least 30 days, promoting their focus on immuno-inflammatory diseases.
Price reaction · baseline $3.05 (2026-03-02 close) · hit pre-market · clean, no other ACRS news in the window
day 0 close
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris is participating in a prominent healthcare conference.
  • The event provides visibility for Aclaris' leadership and pipeline.
  • Webcasts will be accessible for a month, enhancing outreach.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL.
A live and archived webcast of this event will be accessible on theEvents pageof the Aclaris website,www.aclaristx.com. The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris onLinkedIn.

Aclaris Therapeutics Contact:

Will RobertsSenior Vice PresidentCorporate Communications and Investor Relations(484) 329-2125wroberts@aclaristx.com

Frequently Asked Questions

When will Aclaris participate in the conference?

Aclaris will participate in the conference on March 10, 2026.

Who will represent Aclaris at the event?

CEO Dr. Neal Walker and the senior leadership team will represent Aclaris.

How can I access the conference webcast?

The conference webcast will be available on Aclaris' website for at least 30 days.

What is the focus of Aclaris Therapeutics?

Aclaris focuses on developing treatments for immuno-inflammatory diseases.

ShareAdd on Google
Tags: ACRS Viatris Investor Conferences Healthcare Aclaris Therapeutics Leerink Partners healthcare conference immuno-inflammatory diseases
Last updated: Mar 3, 2026

Biotech snapshot

Cash runway
$171M liquidity · $7M/mo burn
~25 mo
Minimal dilution risk
Lead asset
ATI-045Phase 2
Atopic Dermatitis →

Catalyst track record

+181%
best trade around ACRS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ACRS.

See every catalyst's timing & PoA →